Decision Moments and Pulmonary Embolism Diagnostic Quality in the Emergency Department - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Critical Decision Points and the Quality of Pulmonary Embolism Diagnosis in Emergency Settings

  • By

  • Alexander T. Janke

  • Christopher M. Fung

  • Matthew C. Bombard

  • Seth Krupp

  • J. Adam Oostema

  • Daniel L. Overbeek

  • Matthew Hysell

  • James H. Paxton

  • Giuseppe Perrotta

  • Brett Todd

  • Lauren M. Westafer

  • Geoffrey D. Barnes

  • Colin F. Greineder

  • Keith E. Kocher

  • September 22, 2026

Share

  • 1

    Pulmonary embolism (PE) is often underdiagnosed in emergency departments despite its serious implications and overlapping symptoms with other conditions.

  • 2

    Risk-stratification tools and D-dimer assays are recommended to reduce unnecessary imaging for PE, yet CTPA usage has significantly increased.

  • 3

    The Michigan Emergency Department Improvement Collaborative (MEDIC) aims to enhance PE diagnostic quality through a structured decision-making framework.

  • 4

    A multisite study analyzed clinician decision-making at key moments in PE testing across 29 emergency departments in Michigan.

  • 5

    The study evaluated CTPA diagnostic yield and missed opportunities for PE diagnosis, focusing on clinician variation in testing decisions.

Original Source(s)

Decision Moments and Pulmonary Embolism Diagnostic Quality in the Emergency Department

  • by Alexander T. Janke, Christopher M. Fung, Matthew C. Bombard, Seth Krupp, J. Adam Oostema, Daniel L. Overbeek, Matthew Hysell, James H. Paxton, Giuseppe Perrotta, Brett Todd, Lauren M. Westafer, Geoffrey D. Barnes, Colin F. Greineder, Keith E. Kocher

  • September 22, 2026

Related Content

Two liberations, two physiological targets: implications of the X-COPD trial

Nasal obstruction may worsen OSA indicators

Increases in apnea-hypopnea events were greatest among patients with an elevated baseline index, while evidence supporting mouth taping remained preliminary.

FDA updates PAH label with trial data

In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.